What Does a Gastroparesis Warning Mean for Ozempic Users in Texas?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Awareness to Targeted Legal Inquiry

If you or a loved one has been taking Ozempic and now struggles with persistent nausea, vomiting, or abdominal pain after eating, you may be facing gastroparesis—a condition where the stomach empties too slowly. This concern has grown alongside the medication's widespread use, and understanding the clinical red flags is essential for timely management. Building on decades of medical and public health awareness, this page outlines the key symptoms, FDA warnings, and practical steps for monitoring your health.

The Pharmacological Link Between Ozempic and Gastroparesis

Ozempic, the brand name for semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes. Its pharmacological action includes slowing gastric emptying, a mechanism that contributes to its glucose-lowering effects but also raises concerns about gastrointestinal adverse events. Among these, gastroparesis—a condition characterized by delayed gastric emptying in the absence of mechanical obstruction—has been reported in association with Ozempic use. This section examines the clinical presentation of gastroparesis, the pharmacological link to Ozempic, and the risk and legal considerations for affected patients, particularly in Texas. Gastroparesis presents with symptoms such as nausea, vomiting, early satiety, postprandial fullness, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can lead to malnutrition, weight loss, and severe complications like bezoar formation. In the context of Ozempic, the drug's effect on gastric motility is a known pharmacological property. Clinical trial data show that gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: 32.7% for Ozempic 0.5 mg and 36.4% for Ozempic 1 mg, compared to 15.3% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Discontinuation due to gastrointestinal adverse reactions was also higher: 3.1% for Ozempic 0.5 mg and 3.8% for Ozempic 1 mg, versus 0.4% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific gastrointestinal reactions with a frequency of less than 5% included dyspepsia (1.9% placebo, 3.5% Ozempic 0.5 mg, 2.7% Ozempic 1 mg), gastroesophageal reflux disease (0% placebo, 1.9% Ozempic 0.5 mg, 1.5% Ozempic 1 mg), and gastritis (0.8% placebo, 0.8% Ozempic 0.5 mg, 0.4% Ozempic 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While these data do not explicitly list gastroparesis, the symptoms overlap significantly with those of delayed gastric emptying.

Mechanistic Evidence and Postmarketing Reports

Mechanistically, GLP-1 receptor agonists like Ozempic slow gastric emptying by inhibiting antral contractions and stimulating pyloric tone. This effect is dose-dependent and can persist with chronic use. Postmarketing reports have highlighted rare cases of pulmonary aspiration in patients undergoing elective surgeries or procedures requiring general anesthesia or deep sedation, who had residual gastric contents despite reported adherence to preoperative fasting recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This underscores the potential for clinically significant delayed gastric emptying, which is a hallmark of gastroparesis. The available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration, including whether modifying preoperative fasting recommendations or temporarily discontinuing Ozempic could reduce the incidence of retained gastric contents (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This suggests that the drug's effect on gastric motility may be more pronounced than initially appreciated.

Risk Context and Adequacy of Warnings

From a risk perspective, the adequacy of warnings regarding Ozempic and gastroparesis is a central concern. The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions, but it does not specifically mention gastroparesis as a potential adverse effect. The label notes that gastrointestinal adverse reactions occurred more frequently with Ozempic than placebo and that most reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the label does not explicitly warn about the risk of developing gastroparesis, which is a distinct condition that can persist even after drug discontinuation. This gap in warning may affect patients' ability to make informed decisions about treatment and to recognize early symptoms.

Legal Considerations for Texas Patients

For patients in Texas who have developed gastroparesis after using Ozempic, legal considerations include the statute of limitations for filing a product liability claim. In Texas, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or should have been discovered with reasonable diligence. This timeline is critical because gastroparesis symptoms may develop gradually, and the link to Ozempic may not be immediately apparent. Patients should document the timeline between exposure to Ozempic and the onset of symptoms, as well as any medical diagnoses of gastroparesis. Attorney-related considerations include the need to establish that the drug's warnings were inadequate and that the manufacturer failed to disclose known risks. The postmarketing reports of pulmonary aspiration due to retained gastric contents (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98) may support arguments that the manufacturer was aware of the potential for severe gastric motility issues but did not adequately warn patients or healthcare providers.

Summary of Evidence and Next Steps

In summary, the evidence indicates a plausible link between Ozempic and gastroparesis, supported by the drug's pharmacological effects on gastric emptying and clinical trial data showing increased gastrointestinal adverse reactions. The adequacy of warnings is questionable, as the label does not specifically address gastroparesis. For affected patients in Texas, the statute of limitations imposes a two-year window from discovery of the injury, emphasizing the need for prompt legal consultation. The timeline between exposure and documented harm is a key factor in building a case, and patients should seek legal advice to evaluate their options.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Texas?

In Texas, the statute of limitations for personal injury claims, including product liability for Ozempic-induced gastroparesis, is generally two years from the date the injury was discovered or should have been discovered with reasonable diligence. It is crucial to consult an attorney promptly to ensure your claim is filed within this window.

Does Ozempic cause gastroparesis?

Ozempic (semaglutide) slows gastric emptying as part of its mechanism of action. Clinical trials show increased gastrointestinal adverse reactions compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Postmarketing reports of pulmonary aspiration due to retained gastric contents (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98) further support a link to clinically significant delayed gastric emptying, a hallmark of gastroparesis.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.